TY - JOUR T1 - Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA5463 VL - 54 IS - suppl 63 SP - PA5463 AU - Satenik Harutyunova AU - Nicola Benkamin AU - Christina Eichstaedt AU - Alberto Maria Marra AU - Panagiota Xanthouli AU - Benjamin Egenlauf AU - Ekkehard Grünig Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA5463.abstract N2 - Background: Prostacyclins (PCs) are used as targeted treatment for pulmonary arterial hypertension (PAH). Data regarding safety and long-term outcomes of s.c. and/or i.v. treprostinil (T) administered via s.c. Corno and the implantable LENUS Pro pump in patients with PAH are lacking.Methods: Thirty-seven PAH patients (20 females, 51±15 y.o., mean pulmonary arterial pressure 62.3±14.4 mmHg, cardiac index 2.4±0.7 L/min/m2, 6 WHO functional class II, 26 III, 5 IV) on triple targeted PAH medication (ERA, PDE5 inhibitors and treprostinil s.c.) were clinically assessed every 3 months. Survival rate was analysed using Kaplan Mayer estimation.Results: Patients showed a significant improvement of 6-minute walking distance after 3 (p=0.021), 6 (p=0.033) and 12 months (p=0.042) of s.c. treprostinil treatment. Furthermore, tricuspid annular plane systolic excursion, right atrial and right ventricular area improved after 3 and 6 months s.c. treatment (all p<0.05). After a mean of 6±0.9 months, in 24 patients a Lenus Pro pump system was impended for i.v. of treprostinil. Two pumps required surgical revision after 1.5±1 months, 4 further pumps had to be explanted after 11±12 months. After a mean follow-up of 2.82±1.95 years, 12 patients died, three patients received lung transplantation. Transplant-free survival after 1 year was 85.7%, after 2 years 69.2% and after 3 years 65.3% (Figure).Conclusion: Subcutaneous T as add-on to double combination treatment significantly improved right heart size and function in this patient cohort. In most patients T could be continued i.v. by implanted Lenus Pro pump with a good overall-survival.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5463.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -